South San Francisco- and Cambridge-based venture capital firm Clarus Ventures, LLC, said this morning that it has named two new partners. The firm said that it has promoted Emmett Cunningham to Partner and Scott Requadt as Transactional Partner. Dr. Cunningham has been at Clarus since 2006, and is a director of SARcode and Observer at FerroKin, Pearl, Taligen and Zogenix. Cunningham is also an Adjunct Clinical Professor of Ophthalmology at Stanford. Requadt has been at Clarus since 2005, and is a director at TyRx Pharma and Observer at Biolex, Oxford Immunotec, Link Medicine and Variation. Separately, the firm said it has hired on Edward Scolnick, M.D., as a Venture Partner and Finny Kuruvilla, M.D., Ph.D., as a Principal at the firm's Cambridge offices. Scolnick and Kuruvilla is are both from the Broad Institute at MIT and Harvard.